Switching their focus to the SWOG S1826 clinical trial in Hodgkin’s Lymphoma, Rohit Gosain, MD, Rahul Gosain, MD, and Jonathan Friedberg, MD, MMSc, consider the role of frontline R-AVD versus BV-AVD.
Jonathan Friedberg, MD, MMSc
Articles by Jonathan Friedberg, MD, MMSc
Following their discussion on the phase 3 POLARIX trial in DLBCL, Jonathan Friedberg, MD, MMSc, and the Oncology Brothers consider how frontline polatuzumab vedotin will be used in the real-world setting.
Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Jonathan Friedberg, MD, MMSc, to review data with frontline polatuzumab vedotin in DLBCL from the phase 3 POLARIX trial.